SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess
of $100,000 From Investment in Geron Corporation to Contact Brower Piven
Before the May 13, 2014 Lead Plaintiff Deadline -- GERN
STEVENSON, Md., March 18, 2014 (GLOBE NEWSWIRE) -- Brower Piven, A
Professional Corporation announces that a class action lawsuit has been
commenced in the United States District Court for the Northern District of
California on behalf of purchasers of Geron Corporation ("Geron" or the
"Company") (Nasdaq:GERN) securities during the period between June 16, 2013
and March 11, 2014, inclusive (the "Class Period").
If you have suffered a loss from investment in Geron securities purchased on
or after June 16, 2013 and held through the revelation of negative information
on March 12, 2014, as described below, you may obtain additional information
about this lawsuit and your ability to become a lead plaintiff, at no cost to
you, by contacting Brower Piven at www.browerpiven.com, by email at
email@example.com, by calling 410/415-6616, or at Brower Piven, A
Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153.
Attorneys at Brower Piven have combined experience litigating securities and
class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead
plaintiff.If you wish to choose counsel to represent you and the Class, you
must apply to be appointed lead plaintiff no later than May 13, 2014 and be
selected by the Court.The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a settlement
and how much of a settlement to accept for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the largest loss
from investment in Company units during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants' failure to disclose during the Class
Period that persistent low-grade liver function test abnormalities had been
observed in the Phase 2 study of its drug imetelstat in essential
thrombocythemia or polycythemia vera patients and that there was a high risk
of potential chronic livery injury following long-term exposure to the
drug.According to the complaint, following the Company's announcement on
March 12, 2014 that it had received a verbal notice from the U.S. Food and
Drug Administration that a clinical hold would be placed on imetelstat
clinical trials, the value of Geron shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice.You
need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
Press spacebar to pause and continue. Press esc to stop.